Results 231 to 240 of about 21,080,479 (286)

Pseudoprogression after CAR T-cell therapy mimicking orbital lymphoma relapse. [PDF]

QJM
Miyachi T, Kitadate A, Takahashi N.
europepmc   +1 more source

Lost and found in translation: the value of the human imiquimod model

British Journal of Clinical Pharmacology, EarlyView.
Topical imiquimod (IMQ), a Toll‐like receptor (TLR) 7 agonist, induces transient cutaneous inflammation and is widely used in preclinical research as a ‘psoriasis‐like’ mouse model. However, accumulating evidence indicates substantial divergence between IMQ‐driven biology and human plaque psoriasis pathogenesis.
Anouk C. Meijs, Juliette A. van den Noort, Salma Assil, Naomi B. Klarenbeek, Matthijs Moerland, Tessa Niemeyer‐van der Kolk, Robert Rissmann   +6 more
wiley   +1 more source

Resistance mechanisms and translational bottlenecks in CAR-T cell therapy for pediatric acute lymphoblastic leukemia: a perspective. [PDF]

Front Immunol
Xu J, Sui L, Yang W, Xu L, Shan M.
europepmc   +1 more source

Ferritin as a Nanoparticle Scaffold for Plant‐Produced Next‐Generation Subunit Vaccines

Biotechnology and Bioengineering, EarlyView.
ABSTRACT Protein nanoparticles offer an innovative approach to next‐generation subunit vaccine development by displaying antigenic sequences on the nanoparticle surface. Compared to traditional subunit vaccines, protein nanoparticle vaccines often show improved interaction with the immune system due to their particulate size and repetitive epitope ...
Jordan T. VanderBurgt, Richard Strasser, Christopher P. Garnham, Rima Menassa   +3 more
wiley   +1 more source

Barriers and Blueprints: Next-Generation Engineering Strategies for CAR-T Cell Therapy in Gastrointestinal Tumors. [PDF]

Pharmaceuticals (Basel)
Ismail M, Al-Gizey N, Alabed Z, Mustafa N, Al-Najjar E, Hamdaneh Y, Eid N, Esmail A.   +7 more
europepmc   +1 more source

Isolating T‐Cell Potent Lentiviral Vector Subpopulations through Rational Design of Nanofiber Anion‐Exchange Adsorbents

Biotechnology and Bioengineering, EarlyView.
ABSTRACT Generation of CAR‐T cell therapies relies predominantly on lentiviral vectors (LVs). As in vivo CAR‐T trials progress, demand for larger quantities of higher‐potency LV is expected. However, primary capture by anion‐exchange chromatography (AIEX) remains a major manufacturing bottleneck from use of adsorbents not tailored to LVs, leading to ...
George Pamenter, Gyorgy Ovari, Anurag Kulkarni, Thomas Williams‐Fegredo, Carol Knevelman, Kyriacos Mitrophanous, Lee Davies, Farzad Foroutan, Matthew Townsend, Stephen Goldrick, Daniel G. Bracewell   +10 more
wiley   +1 more source

The three-dimensional perspective of CAR-T cell therapy in autoimmune diseases. [PDF]

EBioMedicine
Shen J, Mao J, Ye Q.
europepmc   +1 more source

Cell and Gene Therapies Manufacturing Challenges and Integrated Good Manufacturing Practices Solutions: A Lifecycle Perspective

Biotechnology and Bioengineering, EarlyView.
Lifecycle perspective on cell and gene therapy manufacturing challenges and enabling GMP solutions. ABSTRACT Cell and gene therapies (CGTs) are revolutionizing modern medicine; however, making these advanced medicines scalable and readily available to commercial manufacturers worldwide is a major challenge. The number of approved CGT products continues
Rajath Samaga, Udisha Singh, Sachin Dattram Pawar   +2 more
wiley   +1 more source

CAR T-cell therapy induced pseudoprogression. [PDF]

Front Immunol
Dean EA.
europepmc   +1 more source